Insider filing · ANVS

Michael B Hoffman bought $2.0M of Annovis Bio (ANVS)

Executed Oct 28 2025, disclosed Nov 12 2025, 15 days later, against a two-business-day limit.

Over the 21 trading sessions from the disclosed entry session (Nov 12 2025), the stock returned +74.7% (delay-adjusted); from the execution session (Oct 28 2025), +127.4%. Derived: entry at the session's open, exit at the close 20 sessions later.

MH Michael B Hoffman Director profile →

Michael B Hoffman (Director) filed 6 Form 4 reports in the trailing twelve months (6 purchases, 0 sales, 1 filed past the two-business-day deadline), most often in Annovis Bio, Inc. (ANVS). Across 5 priced purchase filings, the average 21-session return was +21.1% from execution and +6.9% from disclosure (delay-adjusted; derived). The largest single filing was $2.0M of ANVS (975,610 sh × $2.05, as filed), executed Oct 28 2025.

ANVS Annovis Bio, Inc. ANVS · Healthcare · 7 filings in 24 months ticker →

Healthcare · Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→